Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection
Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection
复制标题
DOI：
10.1016/j.juro.2006.07.054
复制
发表时间：
2006-11-01
影响因子：
6.6
通讯作者：
Sillerud, Laurel O.
中科院分区：
文献类型：
--
作者：
Kline, Eric E.;Treat, Eric G.;Sillerud, Laurel O.
目的：我们比较了柠檬酸盐浓度测量在未经处理的人类精液和前列腺分泌物的控制和活检证实的前列腺癌患者的前列腺特异性抗原检测方面的特异性和敏感性前列腺癌detection.Materials和方法：精液和前列腺分泌物收集活检证实，前列腺癌轴承和noncancer轴承的情况。通过定量体外、高场、水抑制质子核磁共振光谱测定柠檬酸盐浓度。柠檬酸盐和前列腺特异性抗原在我们的研究人群的诊断性能的评估结果进行了ROC curve analysis.Results：柠檬酸盐测定样本从61名参与者，其中16个没有和21个癌症捐赠精液，和17个没有和7个癌症捐赠前列腺液。与对照组相比，癌症患者精液（132.2 +/- 30.1 vs 48.0 +/- 7.9 mM，p < 0.05）和前列腺分泌物（221.4 +/- 55.4 vs 81.5 +/- 36.0 mM，p < 0.05）样本中的平均柠檬酸盐+/- SE低2.7倍。ROC曲线分析显示，测量精液中的柠檬酸盐以及测量前列腺液中的柠檬酸盐用于检测前列腺癌（AUC分别为0.81，95% CI 0.60至0.92和AUC 0.73，95% CI 0.38至0.90，p > 0.05）。ROC曲线分析还表明，测量柠檬酸盐在任一流体优于前列腺特异性抗原测量检测前列腺癌在这些科目（AUC 0.61，95%CI 0.44至0.74）。结论：在体外核磁共振光谱测量的柠檬酸盐浓度在精液或前列腺分泌物优于前列腺特异性抗原检测前列腺癌。
Purpose: We compared the performance of citrate concentration measurements in unprocessed human semen and expressed prostatic secretions from controls and from patients with biopsy confirmed prostate cancer to that of prostate specific antigen testing with respect to specificity and sensitivity for prostate cancer detection.Materials and Methods: Semen and expressed prostatic secretions were collected in biopsy proven, prostate cancer bearing and noncancer bearing cases. Citrate concentrations were determined by quantitative in vitro, high field, water suppressed proton nuclear magnetic resonance spectroscopy. Assessments of the diagnostic performance of citrate and prostate specific antigen results in our study populations were made by ROC curve analysis.Results: Citrate was measured in samples from 61 participants, of whom 16 without and 21 with cancer donated semen, and 17 without and 7 with cancer donated expressed prostatic secretions. Mean citrate +/- SE compared to that in controls was 2.7-fold lower in patients with cancer samples in semen (132.2 +/- 30.1 vs 48.0 +/- 7.9 mM, p < 0.05) and expressed prostatic secretions (221.4 +/- 55.4 vs 81.5 +/- 36.0 mM, p < 0.05). ROC curve analysis showed that measurements of citrate in semen performed as well as measurements of citrate in expressed prostatic secretion for detecting prostate cancer (AUC 0.81, 95% CI 0.60 to 0.92 and AUC 0.73, 95% CI 0.38 to 0.90, respectively, p > 0.05). ROC curve analysis also showed that the measurement of citrate in either fluid outperformed prostate specific antigen measurement for detecting prostate cancer in these subjects (AUC 0.61, 95% CI 0.44 to 0.74).Conclusions: In vitro nuclear magnetic resonance spectroscopic measurement of the citrate concentration in semen or expressed prostatic secretions outperforms prostate specific antigen testing for detecting prostate cancer.